Emgality
(galcanezumab-gnlm)Emgality 100 MG in 1 ML Prefilled SyringeEmgality 120 MG in 1 ML Auto-Injector
View 1 more
NO BOXED WARNING
Dosage & administration
drug label
Emgality prescribing information
Financial Assistance
Financial Assistance Programs
Emgality retails for $679 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Emgality for significantly less. Review the program information below to determine what program can offer your patient the most benefits.CoPay Card Program$0 Co Pay
Available for
commercial
Program Details
- $679 for 120mg Pen
- Program Expires 12/31/2023
- $4900 Annual Cap
Forms
Foundation ProgramFirst dose for $0
Available for
medicare
uninsured
Eligibility requirements
- Uninsured
- Medicare Part D
- Household annual adjusted gross income <= 400% FPL.
Forms
patient education
Emgality patient education
Getting started on Emgality
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Learn More
people also ask
Emgality FAQs
What is the Pregnancy Exposure Registry for EMGALITY?The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus.
How can pregnant women enroll in the Pregnancy Exposure Registry?Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.
What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine?The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.
Are there any known risks associated with the use of EMGALITY during pregnancy?There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development.
Can EMGALITY be used during lactation?There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.
Is EMGALITY safe for pediatric use?Safety and effectiveness in pediatric patients have not been established.
Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients?Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
FAQ Data Source